Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib plus ramucirumab versus erlotinib plus placebo in previously untreated EGFR-mutant metastatic non-small cell lung cancer
2014-004824-22Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ramucirumab and erlotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Eli Lilly and Company. Started Mar 2015; status: active.
02
Drugs
ramucirumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-004824-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004824-22.